Key result
Medical genetics increasingly explains variations in HF phenotypes, disease clusters, and treatment responses.
This review highlights the developing role of medical genetics in understanding heart failure phenotypes and treatment responses, noting that current genetic information often exceeds clinical applicability.
Genetic insights into HF phenotypes should not yet alter management; leaves open translational validation needs.
Congestive heart failure (CHF) is a chronic and often devastating cardiovascular disorder with no cure. There has been much advancement in the last two decades that has seen improvements in morbidity and mortality. Clinicians have also noted variations in the responses to therapies. More detailed observations also point to clusters of diseases, phenotypic groupings, unusual severity and the rates at which CHF occurs. Medical genetics is playing an increasingly important role in answering some of these observations. This developing field in many respects provides more information than is currently clinically applicable. This includes making sense of the established single gene mutations or uncommon private mutations. In this thematic series which discusses the many factors that could be relevant for CHF care, once established treatments are available in the communities; this section addresses a contextual role for medical genetics.
No takes yet. Share an insight, caveat, or question.
Iyngkaran et al. (2016) conducted a review in Congestive heart failure (CHF). Medical genetics was evaluated. Medical genetics plays an increasingly important contextual role in understanding variations in congestive heart failure phenotypes, disease clusters, and treatment responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: